<p><strong><em>公司与新的西海岸客户群体创造了数百万美元的收入</em></strong></p>
<p><strong><em>美国西部现在占公司客户诊所足迹的超过 10%</em></strong></p>
<p>密歇根州威克索姆 --（商业资讯）--Rockwell Medical, Inc.（“公司”）（纳斯达克：RMTI），一家开发、制造、商业化和分销血液透析产品组合的医疗保健公司，今天宣布公司在美国西部新增了 30 个客户。</p>
<p>“在过去几个月中，血液透析浓缩剂的供应链经历了重大干扰，特别是在美国西部，” Rockwell Medical 的总裁兼首席执行官 Mark Strobeck 博士表示。“历史上，西部的血液透析浓缩剂供应商选择极为有限。为了稳定供应链并确保对处于终末期肾病的脆弱患者提供不间断的生命维持治疗，Rockwell Medical 迅速采取行动，通过快速扩大生产和扩展我们的物流基础设施来确保产品的可用性，以满足重要的客户需求。因此，我们现在能够通过可靠的供应链和高质量的血液透析产品为整个美国大陆的客户提供服务。”</p>
<p>公司的新客户群体包括但不限于一个大型的综合性非营利医疗系统；一个为加利福尼亚州患者提供服务的全面慢性肾病和透析护理组织；一个社区基础的非营利急救医院；以及一个创新驱动的肾脏护理中心，开发和提供下一代人工肾解决方案。凭借其扩展的分销能力，Rockwell Medical 现在成为美国西部一个可行的替代供应商，能够更高效地向该地区现有客户交付血液透析浓缩剂产品。</p>
<p><strong>关于 Rockwell Medical</strong></p>
<p>Rockwell Medical, Inc.（纳斯达克：RMTI）是一家开发、制造、商业化和分销血液透析产品组合的医疗保健公司，服务于全球的透析提供者。Rockwell Medical 的使命是为透析诊所及其服务的患者提供最高质量的产品，并提供行业内最佳的客户服务。Rockwell 专注于创新的长期增长战略，提升其产品、流程和人员，使公司能够为医疗保健系统提供卓越的价值，并对血液透析患者的生活产生积极影响。血液透析是终末期肾病治疗中最常见的形式，通常在独立的门诊透析中心、医院门诊中心、熟练护理设施或患者的家中进行。Rockwell Medical 的产品对处于终末期肾病的脆弱患者至关重要，公司在提供无与伦比的可靠性和客户服务方面不遗余力。Rockwell Medical 在 2023 年、2024 年和 2025 年被认证为 “最佳工作场所”，并在 2024 年和 2025 年被评为《财富》制造与生产最佳工作场所。Rockwell Medical 致力于提供生命维持透析解决方案。有关更多信息，请访问 www.rockwellmed.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的某些声明可能构成联邦证券法意义上的 “前瞻性声明”。诸如 “可能”、“或许”、“将”、“应该”、“相信”、“期望”、“预期”、“估计”、“继续”、“能够”、“可以”、“会”、“开发”、“计划”、“潜在”、“预测”、“预测”、“项目”、“打算”、“期待”、“保持信心”、“决心”、“致力于”、“在轨道上”、“坚定我们的愿景”、“努力”、“朝着”、“专注于”、“寻求” 等词语，及这些术语的否定形式，以及关于意图、信念或当前预期的类似表达，均为前瞻性声明。虽然 Rockwell Medical 认为这些前瞻性声明是合理的，但不应对任何此类前瞻性声明过度依赖，这些声明基于我们在本发布日期可获得的信息。这些前瞻性声明基于当前的估计和假设，并受到各种风险和不确定性的影响（包括但不限于 Rockwell Medical 在 SEC 文件中列出的那些风险），其中许多超出我们的控制范围并可能发生变化。实际结果可能会有重大不同。风险和不确定性包括但不限于在我们截至 2024 年 12 月 31 日的 10-K 表格年度报告的 “风险因素” 部分中更全面讨论的那些风险，相关描述可能在我们未来向 SEC 提交的任何报告中进行修订或更新。Rockwell Medical 明确声明不承担更新我们的前瞻性声明的任何义务，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMTI5MTU2NzlyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMTI5MTU2NzlyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260112915679/en/</p>
<p>(248) 432-1362</p>
<p>IR@RockwellMed.com</p>
<p>来源：Rockwell Medical</p>

Rockwell医疗

<p>Rockwell Medical, Inc.（纳斯达克代码：RMTI）在美国西部新增了 30 个客户，目前客户基础的 10% 以上来自于此。这一扩展是在血液透析浓缩液供应链出现中断的情况下进行的。公司已扩大生产和物流以满足需求，服务于多样化的医疗机构。Rockwell Medical 旨在提供高质量的血液透析产品和卓越的客户服务，巩固其作为该地区可靠供应商的地位</p>

<p><strong><em>The Company generates multi-million dollars in revenue with new west coast customer base</em></strong></p>
<div class="lb-trans"><p><strong><em>公司与新的西海岸客户群体创造了数百万美元的收入</em></strong></p>
</div><p><strong><em>The Western U.S. now accounts for more than 10% of the Company's customer clinic footprint</em></strong></p>
<div class="lb-trans"><p><strong><em>美国西部现在占公司客户诊所足迹的超过 10%</em></strong></p>
</div><p>WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the &#34;Company&#34;) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has added 30 new customers in the western portion of the United States.</p>
<div class="lb-trans"><p>密歇根州威克索姆 --（商业资讯）--Rockwell Medical, Inc.（“公司”）（纳斯达克：RMTI），一家开发、制造、商业化和分销血液透析产品组合的医疗保健公司，今天宣布公司在美国西部新增了 30 个客户。</p>
</div><p>&#34;Over the past several months, the hemodialysis concentrates supply chain has experienced meaningful disruption, particularly in the western United States,&#34; said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. &#34;Historically, hemodialysis concentrates supplier options in the west have been extremely limited. To stabilize the supply chain and ensure uninterrupted access to life-sustaining treatments for vulnerable patients with end-stage kidney disease, Rockwell Medical moved quickly to ensure product availability by rapidly scaling production and expanding our logistics infrastructure to address vital customer demand. As a result, we are now serving customers across the continental United States with our reliable supply chain and high-quality hemodialysis products.&#34;</p>
<div class="lb-trans"><p>“在过去几个月中，血液透析浓缩剂的供应链经历了重大干扰，特别是在美国西部，” Rockwell Medical 的总裁兼首席执行官 Mark Strobeck 博士表示。“历史上，西部的血液透析浓缩剂供应商选择极为有限。为了稳定供应链并确保对处于终末期肾病的脆弱患者提供不间断的生命维持治疗，Rockwell Medical 迅速采取行动，通过快速扩大生产和扩展我们的物流基础设施来确保产品的可用性，以满足重要的客户需求。因此，我们现在能够通过可靠的供应链和高质量的血液透析产品为整个美国大陆的客户提供服务。”</p>
</div><p>The Company’s new customer base includes, but is not limited to, a large, integrated, non-profit healthcare system; a comprehensive chronic kidney disease and dialysis care organization serving patients throughout California; a community-based, non-profit acute care hospital; and an innovation-driven renal care center developing and delivering next-generation artificial kidney solutions. With its expanded distribution capabilities, Rockwell Medical is now a viable alternative supplier in the western United States and is able to more efficiently deliver hemodialysis concentrates products to its existing customers with facilities in that region.</p>
<div class="lb-trans"><p>公司的新客户群体包括但不限于一个大型的综合性非营利医疗系统；一个为加利福尼亚州患者提供服务的全面慢性肾病和透析护理组织；一个社区基础的非营利急救医院；以及一个创新驱动的肾脏护理中心，开发和提供下一代人工肾解决方案。凭借其扩展的分销能力，Rockwell Medical 现在成为美国西部一个可行的替代供应商，能够更高效地向该地区现有客户交付血液透析浓缩剂产品。</p>
</div><p><strong>About Rockwell Medical</strong></p>
<div class="lb-trans"><p><strong>关于 Rockwell Medical</strong></p>
</div><p>Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing &amp; Production™ in 2024 and 2025, Rockwell Medical is <em>Driven to Deliver Life-Sustaining Dialysis Solutions™</em>. For more information, visit www.rockwellmed.com.</p>
<div class="lb-trans"><p>Rockwell Medical, Inc.（纳斯达克：RMTI）是一家开发、制造、商业化和分销血液透析产品组合的医疗保健公司，服务于全球的透析提供者。Rockwell Medical 的使命是为透析诊所及其服务的患者提供最高质量的产品，并提供行业内最佳的客户服务。Rockwell 专注于创新的长期增长战略，提升其产品、流程和人员，使公司能够为医疗保健系统提供卓越的价值，并对血液透析患者的生活产生积极影响。血液透析是终末期肾病治疗中最常见的形式，通常在独立的门诊透析中心、医院门诊中心、熟练护理设施或患者的家中进行。Rockwell Medical 的产品对处于终末期肾病的脆弱患者至关重要，公司在提供无与伦比的可靠性和客户服务方面不遗余力。Rockwell Medical 在 2023 年、2024 年和 2025 年被认证为 “最佳工作场所”，并在 2024 年和 2025 年被评为《财富》制造与生产最佳工作场所。Rockwell Medical 致力于提供生命维持透析解决方案。有关更多信息，请访问 www.rockwellmed.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the federal securities laws. Words such as, &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;can,&#34; &#34;would,&#34; &#34;develop,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;forecast,&#34; &#34;project,&#34; &#34;intend,&#34; &#34;look forward to,&#34; &#34;remain confident,&#34; “are determined,” “are committed to,” “are on track,” “are resolute in our vision,” &#34;work to,&#34; &#34;drive towards,&#34; “focused on,” “seeks to” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the &#34;Risk Factors&#34; section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.</p>
<div class="lb-trans"><p>本新闻稿中的某些声明可能构成联邦证券法意义上的 “前瞻性声明”。诸如 “可能”、“或许”、“将”、“应该”、“相信”、“期望”、“预期”、“估计”、“继续”、“能够”、“可以”、“会”、“开发”、“计划”、“潜在”、“预测”、“预测”、“项目”、“打算”、“期待”、“保持信心”、“决心”、“致力于”、“在轨道上”、“坚定我们的愿景”、“努力”、“朝着”、“专注于”、“寻求” 等词语，及这些术语的否定形式，以及关于意图、信念或当前预期的类似表达，均为前瞻性声明。虽然 Rockwell Medical 认为这些前瞻性声明是合理的，但不应对任何此类前瞻性声明过度依赖，这些声明基于我们在本发布日期可获得的信息。这些前瞻性声明基于当前的估计和假设，并受到各种风险和不确定性的影响（包括但不限于 Rockwell Medical 在 SEC 文件中列出的那些风险），其中许多超出我们的控制范围并可能发生变化。实际结果可能会有重大不同。风险和不确定性包括但不限于在我们截至 2024 年 12 月 31 日的 10-K 表格年度报告的 “风险因素” 部分中更全面讨论的那些风险，相关描述可能在我们未来向 SEC 提交的任何报告中进行修订或更新。Rockwell Medical 明确声明不承担更新我们的前瞻性声明的任何义务，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMTI5MTU2NzlyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260112915679r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260112915679/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260112915679/en/</p>
</div><p>(248) 432-1362</p>
<div class="lb-trans"><p>(248) 432-1362</p>
</div><p>IR@RockwellMed.com</p>
<div class="lb-trans"><p>IR@RockwellMed.com</p>
</div><p>Source: Rockwell Medical</p>
<div class="lb-trans"><p>来源：Rockwell Medical</p>
</div>

Rockwell 医疗在西部新增 30 个客户 | RMTI 股票新闻